Comprehensive Ablative Radiation Therapy for Neuroendocrine Carcinoma
This trial will test whether combining immunotherapy with radiation therapy can effectively treat Merkel cell carcinoma.
- Cutaneous Neuroendocrine Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Could you explain what risks are associated with Comprehensive Ablative Radiation Therapy?
"While Phase 2 trials lack the data to support efficacy, there is some evidence that Comprehensive Ablative Radiation Therapy is safe. Thus, we give it a score of 2."
Are there any slots left for volunteers in this experiment?
"This is accurate. Based on the information available from clinicaltrials.gov, this study posted on 3/8/2021 and last updated 9/21/2022 is looking for 18 participants to be enrolled at 7 different locations."
What percentage of hospitals are participating in this research?
"7 different locations, including ones in Basking Ridge, Commack and New York, are currently enrolling patients for this study. To reduce the amount of travelling required, please select the closest location to you."
How many men and women are enrolled in this research project?
"The clinical trial is currently ongoing, as reflected by the data on clinicaltrials.gov. It began on 3/8/2021 and was updated most recently on 9/21/2022. The study needs 18 participants who can be found at 7 sites."
Have there been other tests like this one in the past?
"There have been a total of 47 clinical trials for Comprehensive Ablative Radiation Therapy since 2014. The most recent study is still active, having begun in 2020. A total of 116 studies are currently underway across 1024 cities and 52 countries."
What other medical studies have there been on Comprehensive Ablative Radiation Therapy?
"At the moment, there are a total of 116 ongoing clinical trials for Comprehensive Ablative Radiation Therapy (CAR-T). 10 of these live trials are currently in Phase 3. The majority of studies related to CAR-T are based in Barcelona and South Dakota; however, there are 3692 locations worldwide where these trials are taking place."